Jorge E Cortes joins us at the EHA annual meeting in Amsterdam to discuss the most important advances in the treatment and management of acute myeloid leukaemia and provide an overview of promising emerging therapeutic targets.
Questions
1. What have been the most important recent advances in the treatment of acute myeloid leukaemia (AML)? (0:05)
2. What are the major challenges in the management of adverse events in the treatment of AML and how may they be resolved? (0:55)
3. What is the rationale for targeting IDH1 mutations in patients with AML? (2:07)
4. Can you tell us a little about the phase I study of FT-2102? (3:25)
5. What other emerging therapeutic targets seems promising in AML? (5:22)
Filmed at the European Hematology Association (EHA) 24th congress 2019, Amsterdam, Netherlands.
touchONCOLOGY.com is an independent information resource supporting physicians, clinicians and leading industry professionals in continuously developing their knowledge, effectiveness and productivity, via free-to-access content in multimedia formats.
